Drug Approval | July 03, 2023
Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Prime Minister said that it is a huge day for health in Gujarat and congratulated everyone associated with these projects for completing them on time.
Subscribe To Our Newsletter & Stay Updated
